Fig. 6.

Bioprinted liver cancer models: A. (a) Schematic of the combinatorial printing process for Alginate hydrogel and hepacyte cells. (b) Fluorescence images of bioprinted hESC-derived hepatocytes: a 3D stack of hepatocyte-like cells printed in hydrogel, measured one hour after printing displaying live cells in green and dead cells in red (c) 2D cells collected from the alginate at day-23 indicating albumin expression in green and cell nuclei (DAPI) in blue. B. (a) The bioprinted model of hepatocellular carcinoma (3DP-HepG2) directly after printing (b) Proliferation rates of cells in 3DP-HepG2 and in its 2D counterpart (2D-HepG2) at different time points. (c) Dose-effect curves of cisplatin, sorafenib, and regorafenib in the 3DP-HepG2 and 2D-HepG2 models post-72 h drug treatment. Fig. A is reproduced from Ref. [209] under creative commons attribution license (CC-BY-3.0). Fig. B is reproduced from Ref. [212] under creative commons license (CC-BY-4.0).